

Study Number: 108020005
Test Type: 5-Day Toxicity
Route: Whole-Body Inhalation
Species/Strain: Mouse/B6D2F1/Crl

PA41: Clinical Chemistry Summary
Test Compound: 1,4-Dichlorobenzene
CAS Number: 106-46-7

Date Report Requested: 09/26/2025
Time Report Requested: 14:24:11
Lab: Battelle

Study Number: 108020005
Study Sex: Female
PWG Approval Date: See web page for date of PWG Approval
Version: v1.7.2-6-ge85fa364
Stat Version: 2023.02.27S

Study Number: 108020005
Test Type: 5-Day Toxicity
Route: Whole-Body Inhalation
Species/Strain: Mouse/B6D2F1/Crl

PA41: Clinical Chemistry Summary
Test Compound: 1,4-Dichlorobenzene
CAS Number: 106-46-7

Date Report Requested: 09/26/2025
Time Report Requested: 14:24:11
Lab: Battelle

Female: Core Animals

	Phase Day	Treatment Groups (ppm)				
		0	1	10	50	150
Urea Nitrogen (mg/dL)	SD 5	21.0 ± 1.0 (3)	15.0 (1)	15.5 ± 0.5 (2)	NA	20.0 (1)
Percent of Control			71.4	73.8		95.2
Creatinine (mg/dL)	SD 5	0.21 ± 0.01 (8)	0.20 ± 0.00 (2)	0.20 ± 0.00 (2)	0.20 ± 0.00 (4)	0.20 ± 0.00 (2)
Percent of Control			94.1	94.1	94.1	94.1
Glucose (mg/dL)	SD 5	195.3 ± 28.3 (4) *	176.0 (1)	142.5 ± 0.5 (2)	NA	164.0 (1)
Percent of Control			90.1	73.0		84.0
Total Protein (g/dL)	SD 5	5.90 ± 0.06 (3)	5.40 (1)	5.85 ± 0.15 (2)	NA	6.10 (1)
Percent of Control			91.5	99.2		103.4
Globulin (g/dL)	SD 5	1.50 ± 0.06 (3) *	1.40 (1)	1.55 ± 0.05 (2)	NA	1.70 (1)
Percent of Control			93.3	103.3		113.3
A/G Ratio	SD 5	2.94 ± 0.11 (3) **	2.86 (1)	2.78 ± 0.03 (2)	NA	2.59 (1)
Percent of Control			97.1	94.3		88.0
Albumin (g/dL)	SD 5	4.35 ± 0.04 (8)	4.13 ± 0.13 (3)	4.27 ± 0.07 (3)	4.33 ± 0.11 (4)	4.33 ± 0.08 (4)
Percent of Control			95.0	98.1	99.4	99.4
Cholesterol (mg/dL)	SD 5	124.3 ± 3.6 (8) **	113.7 ± 5.2 (3)	117.7 ± 2.7 (3)	126.5 ± 9.0 (4)	159.3 ± 4.4 (4) *
Percent of Control			91.5	94.7	101.8	128.2
Triglyceride (mg/dL)	SD 5	128.8 ± 7.0 (6)	144.5 ± 18.5 (2)	123.5 ± 5.5 (2)	159.0 ± 49.0 (2)	139.0 ± 13.0 (2)
Percent of Control			112.2	95.9	123.4	107.9
Alanine Aminotransferase (IU/L)	SD 5	41.2 ± 7.6 (9) *	41.0 ± 9.8 (4)	29.7 ± 2.7 (3)	42.0 ± 3.0 (2)	38.8 ± 6.1 (4)
Percent of Control			99.5	72.0	101.9	94.0
Alkaline Phosphatase (IU/L)	SD 5	250.8 ± 10.7 (8)	250.0 ± 18.0 (2)	230.5 ± 11.5 (2)	248.0 ± 12.0 (4)	232.0 ± 22.0 (2)
Percent of Control			99.7	91.9	98.9	92.5

Study Number: 108020005
Test Type: 5-Day Toxicity
Route: Whole-Body Inhalation
Species/Strain: Mouse/B6D2F1/Crl

PA41: Clinical Chemistry Summary
Test Compound: 1,4-Dichlorobenzene
CAS Number: 106-46-7

Date Report Requested: 09/26/2025
Time Report Requested: 14:24:11
Lab: Battelle

Female: Core Animals

	Phase Day	Treatment Groups (ppm)				
		0	1	10	50	150
Aspartate Aminotransferase (U/L) Percent of Control	SD 5	56.75 ± 1.97 (4)	48.00 (1) 84.6	59.50 ± 0.50 (2) 104.8	NA	59.00 ± 12.00 (2) 104.0
Creatine Kinase (IU/L) Percent of Control	SD 5	291.9 ± 97.5 (8)	223.0 ± 64.4 (4) 76.4	162.3 ± 36.7 (3) 55.6	292.5 ± 85.7 (4) 100.2	199.8 ± 62.0 (4) 68.4
Sorbitol Dehydrogenase (IU/L) Percent of Control	SD 5	27.1 ± 1.1 (6)	23.5 ± 2.3 (2) 86.6	19.1 ± 1.8 (2) 70.2	17.6 ± 9.9 (2) 64.7	25.5 (1) 94.0
Bile salt/acids (µmol/L) Percent of Control	SD 5	6.3 ± 1.3 (6)	2.0 (1) 31.6	5.5 ± 0.5 (2) 86.8	3.0 (1) 47.4	3.5 ± 1.5 (2) 55.3

Study Number: 108020005
Test Type: 5-Day Toxicity
Route: Whole-Body Inhalation
Species/Strain: Mouse/B6D2F1/Crl

PA41: Clinical Chemistry Summary
Test Compound: 1,4-Dichlorobenzene
CAS Number: 106-46-7

Date Report Requested: 09/26/2025
Time Report Requested: 14:24:11
Lab: Battelle

Female: Core Animals

	Phase Day	Treatment Groups
		400
Urea Nitrogen (mg/dL)	SD 5	22.0 ± 2.0 (2)
Percent of Control		104.8
Creatinine (mg/dL)	SD 5	0.20 ± 0.00 (2)
Percent of Control		94.1
Glucose (mg/dL)	SD 5	137.5 ± 13.5 (2)
Percent of Control		70.4
Total Protein (g/dL)	SD 5	6.85 ± 0.05 (2)
Percent of Control		116.1
Globulin (g/dL)	SD 5	2.10 ± 0.00 (2)
Percent of Control		140.0
A/G Ratio	SD 5	2.26 ± 0.02 (2) *
Percent of Control		76.9
Albumin (g/dL)	SD 5	4.70 ± 0.06 (3)
Percent of Control		108.0
Cholesterol (mg/dL)	SD 5	269.3 ± 15.1 (3) *
Percent of Control		216.8
Triglyceride (mg/dL)	SD 5	173.5 ± 31.5 (2)
Percent of Control		134.7
Alanine Aminotransferase (IU/L)	SD 5	80.3 ± 16.4 (4)
Percent of Control		194.7
Alkaline Phosphatase (IU/L)	SD 5	196.0 ± 8.0 (2)
Percent of Control		78.2

Study Number: 108020005
Test Type: 5-Day Toxicity
Route: Whole-Body Inhalation
Species/Strain: Mouse/B6D2F1/Crl

PA41: Clinical Chemistry Summary
Test Compound: 1,4-Dichlorobenzene
CAS Number: 106-46-7

Date Report Requested: 09/26/2025
Time Report Requested: 14:24:11
Lab: Battelle

Female: Core Animals

	Phase Day	Treatment Groups
		400
Aspartate Aminotransferase (U/L) Percent of Control	SD 5	85.00 ± 32.00 (2) 149.8
Creatine Kinase (IU/L) Percent of Control	SD 5	178.3 ± 35.6 (3) 61.1
Sorbitol Dehydrogenase (IU/L) Percent of Control	SD 5	42.4 ± 15.7 (2) 156.3
Bile salt/acids (µmol/L) Percent of Control	SD 5	7.5 ± 0.5 (2) 118.4

Study Number: 108020005
Test Type: 5-Day Toxicity
Route: Whole-Body Inhalation
Species/Strain: Mouse/B6D2F1/Crl

PA41: Clinical Chemistry Summary
Test Compound: 1,4-Dichlorobenzene
CAS Number: 106-46-7

Date Report Requested: 09/26/2025
Time Report Requested: 14:24:11
Lab: Battelle

LEGEND

Values given as mean \pm SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100.

SD = Study Day

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Data with sample size of 1 in the treatment group were included in trend test, but excluded from the multiple comparisons tests.

Statistical significance for the control group indicates a significant trend test.

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.

* Statistically significant at $p \leq 0.05$

** Statistically significant at $p \leq 0.01$

Control and treated animals' total and direct bilirubin were below linearity, consistent with normal baseline concentrations and indicating no effect; these values are not reported.

Clinical chemistry data not reported was removed as an outlier, or was due to pre-analytical or analytical conditions or errors including but not limited to: below linearity, short sample, quantity not sufficient, or extreme hemolysis.

NA = No measurements for this endpoint at the given concentration due to insufficient volume available for analysis.

**** END OF REPORT ****